Evaluating the reliability and construct validity of the Eckardt symptom score as a measure of achalasia severity

T H Taft, D A Carlson, J Triggs, J Craft, K Starkey, R Yadlapati, D Gregory, J E Pandolfino, T H Taft, D A Carlson, J Triggs, J Craft, K Starkey, R Yadlapati, D Gregory, J E Pandolfino

Abstract

Background: Achalasia is a disease of mechanical esophageal dysfunction characterized by dysphagia, chest pain, regurgitation, and malnutrition. The Eckardt symptom score (ESS) is the gold standard self-report assessment tool. Current guidelines outline a three-step approach to patient reported outcomes measure design. Developed prior to these policies, the ESS has not undergone rigorous testing of its reliability and validity.

Methods: Adult achalasia patients retrospectively identified via a patient registry were grouped based on treatment history. Patients were grouped PREPOST (completed ESS, GERDQ, brief esophageal dysphagia questionnaire, NIH PROMIS Global Health, high resolution manometry, timed barium esophagram prior to treatment and after) and POST (completed measures only after treatment). Clinical characteristics, treatment type and date were obtained via medical record. Standardized psychometric analyses for reliability and construct validity were performed.

Key results: 107 patients identified; 83 POST and 24 PREPOST. The ESS has fair internal consistency and split-half reliability with a single factor structure. Dysphagia accounts for half the variance in ESS, while chest pain and weight loss account for 10% each. Pre-post-surgical assessment demonstrates improvements in ESS, except for weight loss. Effect sizes range from 0.24 to 2.53, with greatest change in regurgitation. Validity of the ESS is supported by modest correlations with GERDQ, HRQOL, and physiological data.

Conclusions & inferences: The ESS demonstrates fair reliability and validity, with a single factor structure mostly explained by dysphagia. Based on psychometric findings, weight loss and chest pain items may be decreasing ESS reliability and validity. Further assessment of the ESS under FDA guidelines is warranted.

Keywords: Eckardt symptom score; achalasia; patient reported outcomes.

© 2018 John Wiley & Sons Ltd.

References

    1. Yasawy MI. Diagnosis and treatment of achalasia patients: a ten-year review of the clinical features. Hepatogastroenterology. 2014;61:1611–6.
    1. O’Neill OM, Johnston BT, Coleman HG. Achalasia: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2013;19:5806–12.
    1. Bredenoord AJ, Fox M, Kahrilas PJ, et al. Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol Motil. 2012;24(Suppl 1):57–65.
    1. Roman S, Huot L, Zerbib F, et al. High-Resolution Manometry Improves the Diagnosis of Esophageal Motility Disorders in Patients With Dysphagia: A Randomized Multicenter Study. Am J Gastroenterol. 2016
    1. Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol. 2013;108:1238–49. quiz 1250.
    1. Boeckxstaens GE, Annese V, des Varannes SB, et al. Pneumatic dilation versus laparoscopic Heller’s myotomy for idiopathic achalasia. N Engl J Med. 2011;364:1807–16.
    1. Persson J, Johnsson E, Kostic S, et al. Treatment of achalasia with laparoscopic myotomy or pneumatic dilatation: long-term results of a prospective, randomized study. World J Surg. 2015;39:713–20.
    1. Borges AA, Lemme EM, Abrahao LJ, Jr, et al. Pneumatic dilation versus laparoscopic Heller myotomy for the treatment of achalasia: variables related to a good response. Dis Esophagus. 2014;27:18–23.
    1. Chrystoja CC, Darling GE, Diamant NE, et al. Achalasia-Specific Quality of Life After Pneumatic Dilation or Laparoscopic Heller Myotomy With Partial Fundoplication: A Multicenter, Randomized Clinical Trial. Am J Gastroenterol. 2016;111:1536–1545.
    1. Novais PA, Lemme EM. 24-h pH monitoring patterns and clinical response after achalasia treatment with pneumatic dilation or laparoscopic Heller myotomy. Aliment Pharmacol Ther. 2010;32:1257–65.
    1. Gockel I, Junginger T. The value of scoring achalasia: a comparison of current systems and the impact on treatment–the surgeon’s viewpoint. Am Surg. 2007;73:327–31.
    1. Rohof WO, Salvador R, Annese V, et al. Outcomes of treatment for achalasia depend on manometric subtype. Gastroenterology. 2013;144:718–25. quiz e13–4.
    1. Eckardt VF, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology. 1992;103:1732–8.
    1. Speight J, Barendse SM. FDA guidance on patient reported outcomes. BMJ. 2010;340:c2921.
    1. Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2009;30:1030–8.
    1. Taft TH, Riehl M, Sodikoff JB, et al. Development and validation of the brief esophageal dysphagia questionnaire. Neurogastroenterol Motil. 2016;28:1854–1860.
    1. Hays RD, Bjorner JB, Revicki DA, et al. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009;18:873–80.
    1. Pandolfino JE, Ghosh SK, Rice J, et al. Classifying esophageal motility by pressure topography characteristics: a study of 400 patients and 75 controls. Am J Gastroenterol. 2008;103:27–37.
    1. Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27:160–74.
    1. Mundfrom D, Shaw D, Ke T. Minimum Sample Size Recommendations for Conducting Factor Analyses. International Journal of Testing. 2005;5:159–168.
    1. Ferketich S. Focus on psychometrics. Aspects of item analysis Res Nurs Health. 1991;14:165–8.
    1. Pardoe EM. Development of a multistage diet for dysphagia. J Am Diet Assoc. 1993;93:568–71.
    1. Fisichella PM, Orthopoulos G, Holmstrom A, et al. The surgical management of achalasia in the morbid obese patient. J Gastrointest Surg. 2015;19:1139–43.
    1. Bedell A, Taft TH, Keefer L, et al. Development of the Northwestern Esophageal Quality of Life Scale: A Hybrid Measure for Use Across Esophageal Conditions. Am J Gastroenterol. 2016;111:493–9.
    1. Taft TH, Kern E, Kwiatek MA, et al. The adult eosinophilic oesophagitis quality of life questionnaire: a new measure of health-related quality of life. Aliment Pharmacol Ther. 2011;34:790–8.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する